Sidebar
This is an old revision of the document!
OHDSI Transfusion Working Group
MISSION
Extend OMOP CDM and Vocabulary and OHDSI analytic platform to support transfusion research
Transfusions are special treatments which are currently in active research by the FDA BEST and the REDS-IV program. The current OMOP CDM allows only partial capture of relevant transfusion information to support the various research use cases (see below). This Working Group intends to close that gap.
* Use Cases:
* Effect of number of units on outcomes * Effect of single donor vs pooled on outcomes * Effect agency blood products are obtained from (such as ARC vs NYBC) on outcomes * Incidence rates of severe outcomes: TRALI, TACO, Sepsis, HTRs, PTP, thrombosis and others * Fatality rates of outcomes * Incidence rates of outcomes by specific blood products transfused: red blood cells, plasma, platelets, full blood * Incidence rates of outcomes by blood component processing: leukocyte reduction, irradiation, pathogen-reduction * Incidence rates of outcomes by indication and associated procedures and other possible risk factors * Incidence rates of outcomes by donor characteristics
* Modelling Isues:
* Detailed facts about transfused units, such as
- Manipulation: cultured enrichment, demineralization, genetical modification,
- Concentration, dosage, portioning and unit of issue,
- Preservation: irradiation and pathogen reduction, transport, storage, cryoprotection,
- monitoring: preparation, processing, mobilization, modification, quarantine,
- Additive, excipient and nutrient content
